Monographie - Tigecycline - Stabilis 4.0

Siste oppdatering :
19/11/2024

Antibiotika

Tigecycline

Injeksjon

Oppløsningsstabilitet

Stabilitet i blandinger

Faktorer som påvirker stabiliteten

Kompatibilitet

Administrasjonsmåte

Referanser

pdf

Kjemisk struktur

Handelsnavn

Handelsnavn

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Eticina	Mexico
Grexyl	Mexico
Linicetil	Mexico
Mrsacin	Tyrkia
Tecygen	Chile
Tigecid	Tyrkia
Tigecilina	Argentina, Chile, Ecuador
Tigecycline	Canada
Tigetop	Chile
Tizoxim	Argentina
Tygacil	Argentina, Belgia, Canada, Chile, Colombia, Danmark, De forente arabiske emirater, Ecuador, Finland, Frankrike, Hellas, Irland, Island, Italia, Japan, Luxembourg, Malaysia, Mexico, Nederland, New Zealand, Norge, Peru, Polen, Portugal, Romania, Saudi-Arabia, Spania, Storbritannia, Sveits, Sverige, Tyrkia, Tyskland, Ungarn, USA, Venezuela, Østerrike
Zomiprerin	Peru

Referanser

Injeksjon

Referanser : Tigecycline

	Type	publikasjon
2262	Journal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Labratorium	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	Journal	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Labratorium	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Labratorium	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Labratorium	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Labratorium	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	plakat	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	Journal	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Journal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	Journal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Journal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales